ASHWINI NEELGUND: Open Payments
NPI 1487869574 · MATAWAN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,760 in 92 payments from 19 companies in 2025. Trend: 2023 $987 · 2024 $1,388 · 2025 $1,760
Food & beverage: $1,760
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $317 |
| ABBVIE INC. | 22 | $253 |
| E.R. Squibb & Sons, L.L.C. | 8 | $245 |
| Alkermes, Inc. | 9 | $160 |
| Neos Therapeutics, LP | 7 | $141 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Bausch Health US, LLC | 4 | $69 |
| Abbott Laboratories | 3 | $68 |
Products named: CAPLYTA, VRAYLAR, COBENFY, Adzenys XR-ODT, INGREZZA, LYBALVI, REXULTI, TRINTELLIX.
Industry payments across NJ — which companies pay providers there.
